NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype.

Epithelial ovarian cancer is the most lethal gynecologic malignancy. In 2012, there were an estimated 22,280 women diagnosed with ovarian cancer with 15,500 deaths [ 1 ]. The five-year overall survival is approximately 45%. Ovarian cancer collectively encompasses multiple histological types. Of these, the papillary serous histology accounts for about 60% [ 2 ]. Less common are mucinous, clear cell, and endometrioid tumors [ 2 ]. Each histological type is distinct with respect to its pathogenesis and clinical behavior, including response to chemotherapy [ 3 ]. Arguably the most important prognostic factor in ovarian cancer is stage. It is plausible that ovarian cancer, like colon or cervical cancer arises from a precursor lesion. Mucinous carcinomas and low grade serous carcinomas have been shown to co-exist with borderline tumors of the corresponding histology [ 4 , 5 ]. Recently, clear cell carcinomas have been shown to arise from areas of atypical endometriosis with loss of expression of ARID1A [ 6 ]. A clear precursor lesion has not been identified for papillary serous carcinomas, which tend to present at an advanced stage. A subset of presumed serous carcinomas of the ovary or fallopian tube, however, may actually arise from intraepithelial carcinomas of the distal fallopian tube [ 7 ]. Lack of identification of a papillary serous precursor has precluded the development of effective screening tests and hampered the elucidation of early carcinogenic events in epithelial ovarian carcinoma. Several regulators of cell fate, most notably P53 [ 8 ], BRCA1/2 [ 9 ], PTEN , and members of the PIK3 pathway [ 10 ] have been investigated in the context of ovarian cancer. Recently identified regulators of cell fate include members of the NOTCH signaling pathway. This signaling pathway is an evolutionarily conserved intercellular communication mechanism, which is mediated by the interaction of receptors and the cognate ligands on the cell membrane of neighboring cells. There are four NOTCH receptors ( NOTCH 1-4) and five canonical ligands (Delta-like 1, 3, and 4 and Jagged-1 and -2) identified in mammals. NOTCH signaling is involved in many cellular processes including cell differentiation, proliferation, survival, and apoptosis. NOTCH signaling contributes to the specification of cell lineages, tissue patterning and morphogenesis, stem cell maintenance, and tissue homeostasis during embryonic development or in adult life [ 11 ]. Abnormal NOTCH signaling is associated with various human cancers. Though classically studied in the context of tumor angiogenesis [ 12 ], NOTCH family members have also been implicated in tumor cell growth and proliferation as well as in the epithelial to mesenchymal transition [ 13 , 14 ]. NOTCH family members function in a cell type-specific and cell context-dependent manner and may function as both oncogenes as well as tumor suppressors. NOTCH 1, 2 and 3, have been implicated in tumor growth regulation with the type of effect being cancer specific. NOTCH 1 overexpression has been shown to promote tumor cell proliferation and invasion in breast cancer [ 15 ] and proliferation in ovarian cancer cell lines [ 16 , 17 ]. In colon cancer, NOTCH 1 expression has been shown to be an adverse prognostic indicator [ 18 ]. NOTCH 3 likewise has also been identified as an oncogene in serous ovarian cancer, which frequently overexpresses NOTCH 3 as a result of gene amplification [ 19 - 21 ]. NOTCH 3 overexpression in serous ovarian carcinomas has been correlated with carboplatin resistance [ 22 ]. In contrast to NOTCH 1 and NOTCH 3, NOTCH 2 has been shown to play a tumor suppressive role in many cancers including colon, medullary thyroid [ 23 ], carcinoid [ 24 ], and colon cancer [ 18 , 25 ] and may correlate with increased differentiation in both colon [ 25 ] and breast cancer [ 26 ]. The role of NOTCH 2 has not been studied in the setting of ovarian cancer. We report here our findings of NOTCH 2 expression in normal ovary, fallopian tube, serous borderline tumors of the ovary and ovarian carcinomas.

Archival pathology specimens were utilized in this study. Tissues were collected from surgical specimens following primary cytoreductive surgery for fallopian tube, primary peritoneal or ovarian cancer, or following surgery for benign gynecologic indications. Specimens were formalin fixed and paraffin embedded at the time of surgery. Tissue microarrays (TMA) containing 61 papillary serous carcinomas (PS), 13 clear cell carcinomas (CC) 30 endometrioid carcinomas (EC), and 15 mucinous carcinomas (MC) (119 cases evaluated) were assembled by three cores (0.6 mm) of tumor from a representative tissue block of each case. All H&E slides were reviewed and the pathologic diagnoses were confirmed. In addition, routine tissue sections of nine serous borderline tumors were also included. The uninvolved ovarian surface epithelium and fallopian tubal epithelium served as normal tissue controls. Immunohistochemistry of NOTCH2 with a rabbit polyclonal antibody to NOTCH2 (Abcam ab8926 1:100 dilution, Abcam, Cambridge, MA) was performed on the 4 micron sections from either TMA or regular tissue blocks as suggested by the manufacturer. This antibody had been previously validated by the manufacturer. Additionally, validation of the antibody was performed within our laboratory. The staining pattern was identical to that of a NOTCH2 antibody from a different manufacturer, was similar to what has previously been described by Zhang et al. in the mouse ovary, and produced a staining pattern distinct from the staining patterns of NOTCH 1 and NOTCH 3 ( Supplement Figure S1 ). Immunohistochemistry of NOTCH2 with a rabbit polyclonal antibody (1:100 dilution, Abcam, Cambridge, MA) was performed on the 4 micron sections from either TMA or regular tissue blocks as suggested by the manufacturer. In brief, the sections were deparaffinized, rehydrated in decreasing concentrations of ethanol, and subjected to antigen retrieval in Target Retrieval Buffer (Dako, Carpinteria, CA) for 30 minutes. The sections were blocked in 3% BSA and incubated with the NOTCH2 antibody for 10 hours at 4°c. After washing with PBS, the sections were incubated with a fluorescent conjugated secondary antibody, Alexa Fluor 488 (Invitrogen), at a dilution of 1:10,000 for 30 min at 25°C. The slides were coverslipped with Vectashield mounting medium containing DAPI for visualization of the nuclei (Vector laboratories, Burlingame, CA). The staining was examined and photographed using a Nikon fluorescent microscopy system with a digital camera. The staining was scored with a two tier system (high or low) independently by three observers based on the intensity and extensiveness of staining. Consensus was reached by re-evaluation at conference on cases with initial disagreement. The data of staining intensities were analyzed using the chi square test included in the Microsoft excel statistical package. A p value of <.05 was considered statistically significant.

As shown in Figure 1A and 1B , NOTCH2 staining was detected in the normal fallopian tubal epithelium and ovarian surface epithelium. The staining was strong and mainly present at the apical membranes and to a lesser extent was also seen at the basal areas of these epithelial cells. The smooth muscle cells of the fallopian tube and ovarian sex cord-stromal cells were consistently negative for NOTCH2 . Four of seven of the serous borderline tumors in this study demonstrated apical distribution of NOTCH2 in the neoplastic cells as seen in the normal fallopian tube and the ovarian surface epithelium; however basal distribution of NOTCH2 was decreased in these cells. A representative specimen is shown in Figure 2A . In the remaining three cases of borderline serous adenoma, the neoplastic cells had intense diffuse cytoplasmic staining of NOTCH2 as seen in the representative specimen in Figure 2B . For the malignant epithelial tumors of the ovary, 52 of 61 (85.2%) PS, eight of 13 (61.5%) CC, and 23 of 30 (76.7%) EC, demonstrated negative or lower NOTCH2 expression than normal fallopian tubal epithelium or ovarian surface epithelium tumors. Figure 3A is a representative PS with negative expression. In contrast, 10 of 15 (66.7%) MC had a high level of NOTCH2 expression and consistently demonstrated intense polarized staining as shown in Figure 3B (P <.001) ( Table 1 ).

In this study, we investigated the expression of NOTCH2 in normal ovarian surface epithelium, fallopian tubal epithelium, and various histologic types of ovarian carcinomas utilizing immunohistochemistry. We have demonstrated that NOTCH2 is cell membrane-associated and expressed both in the apical and basal sides of the cell in the normal ovarian surface epithelium and fallopian tubal epithelium. Epithelial cells demonstrate polarized expression of several other molecules including those integral for the formation of tight junctions [ 27 ]. Further studies are needed to determine whether NOTCH2 is related to the formation and maintenance of epithelial tight junctions on ovarian epithelial cells. Of note, many of the serous borderline tumors studied contained areas in which the polarity of NOTCH2 expression was preserved. Even in those tumors with non-polarized membranous staining, the overall staining intensity was very high. It is not possible from immunohistochemistry observations alone to establish whether the association between high NOTCH2 expression and a non-invasive phenotype will translate into a causal relationship between loss of NOTCH2 and invasion. Further functional studies are needed to explore this. NOTCH2 expression was present in only a small percentage of the papillary serous ovarian cancer specimens. In the context of the tumor suppressive role of NOTCH2 in colon cancer cells, it is plausible that the poorly differentiated serous carcinomas are also down-regulating NOTCH2 . Further studies are needed to clarify whether NOTCH2 down-regulation is an early causal event in high grade serous carcinoma carcinogenesis, or if the present observation is simply coincidental with a less differentiated state. While the endometrioid tumors, and clear cell specimen sets also had more tumors with low NOTCH2 expression than high NOTCH2 expression, the difference was not as pronounced as in the serous histology tumors. While the small number of specimens in these sets limits the conclusions which may be drawn, it is plausible that given the distinct carcinogenic pathways by which these tumors arise, NOTCH2 down-regulation may play a less important role in non-serous carcinomas. Down-regulation of NOTCH2 has also been documented in colon carcinoma. Loss of expression was more commonly associated with poorly differentiated tumors [ 25 ]. Poorly differentiated tumor cells lacking NOTCH2 expression regain it after forced differentiation by butyrate exposure [ 25 ]. Interestingly, NOTCH2 expression was preserved in the majority of the ovarian mucinous tumors in the present study. This is consistent with the clinical behavior of these tumors, which unlike serous tumors, are more commonly low grade and confined to the ovary at the time of diagnosis [ 2 ]. One limitation of this study is that while the NOTCH2 antibody used in this study recognizes the intracellular domain, it does not specifically identify NOTCH2 involved in active signaling. In the case of NOTCH3, however, the expression level of the intracellular domain alone has been shown to correlate with clinical behavior [ 20 , 22 ]. Another limitation of this study is that while expression differences were noted, and expression was lower in poorly differentiated tumors, no direct conclusions may be drawn regarding whether NOTCH2 is affecting tumor behavior. Additionally, it is unclear whether loss of NOTCH2 expression simply coincides with a poorly differentiated state. The present study explores the pattern of NOTCH2 expression in epithelial ovarian cancer. As has been previously demonstrated in colon cancers, NOTCH2 expression was lost in the vast majority of poorly differentiated tumors. It is plausible therefore that NOTCH2 is related to tumor suppression in ovarian cancer as it is in colon cancer. Further functional experiments are required to validate the observations of the present study and to determine the role of NOTCH2 signaling in ovarian cancer cells.